Pillars one and two of the UK’s national testing strategy for COVID-19 announced on 2 April focus on antigen testing ̶ confirmatory tests for those who currently have the virus. Though the size of the challenge of reaching 100,000 coronavirus tests per day is not in question, the technology being employed at the UK’s new testing mega-centers is largely known and worked out already; it is the upscaling that is the bigger challenge.
For the antibody tests now being developed around the globe, the hurdles of identifying the target population, and the specificity and sensitivity of the tests, especially when prevalence (in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?